Cargando…
Metastatic carcinoma of unknown primary with complete metabolic response following sorafenib-based chemotherapy
BACKGROUND: The treatment of carcinoma of unknown primary based on histopathology and immunohistochemistry is generally chemotherapy. The use of molecular markers, genetic profiling platforms, and personalized medicine is under active investigation. CASE REPORT: We report the case of a 56-year-old p...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429643/ https://www.ncbi.nlm.nih.gov/pubmed/30915220 http://dx.doi.org/10.1177/2050313X19838739 |
_version_ | 1783405634858778624 |
---|---|
author | Usón Junior, Pedro Luiz Serrano Wagner, Jairo Corpa, Marcus Vinicius de Nigro Coelho, Iracema Moraes Nagourney, Robert A Yamaguchi, Nise Hitomi |
author_facet | Usón Junior, Pedro Luiz Serrano Wagner, Jairo Corpa, Marcus Vinicius de Nigro Coelho, Iracema Moraes Nagourney, Robert A Yamaguchi, Nise Hitomi |
author_sort | Usón Junior, Pedro Luiz Serrano |
collection | PubMed |
description | BACKGROUND: The treatment of carcinoma of unknown primary based on histopathology and immunohistochemistry is generally chemotherapy. The use of molecular markers, genetic profiling platforms, and personalized medicine is under active investigation. CASE REPORT: We report the case of a 56-year-old patient who presented to medical attention with palpable axillary adenopathy. Biopsy confirmed poorly differentiated adenocarcinoma. Formal staging revealed extensive metastatic disease to bone and liver. Initial chemotherapy proved ineffective. We describe the diagnostic evaluation, treatment, and achievement of durable remission using a novel sorafenib-based drug combination that was chosen through the application of a functional analytic laboratory platform. CONCLUSION: The clinical management of patients with carcinoma of unknown primary continues to present a considerable challenge for practicing oncologists. Laboratory platforms capable of examining cellular response to injury, growth factor withdrawal, and cytotoxic insult at the level of cellular function may provide insights for drug selection in this patient population. |
format | Online Article Text |
id | pubmed-6429643 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-64296432019-03-26 Metastatic carcinoma of unknown primary with complete metabolic response following sorafenib-based chemotherapy Usón Junior, Pedro Luiz Serrano Wagner, Jairo Corpa, Marcus Vinicius de Nigro Coelho, Iracema Moraes Nagourney, Robert A Yamaguchi, Nise Hitomi SAGE Open Med Case Rep Case Report BACKGROUND: The treatment of carcinoma of unknown primary based on histopathology and immunohistochemistry is generally chemotherapy. The use of molecular markers, genetic profiling platforms, and personalized medicine is under active investigation. CASE REPORT: We report the case of a 56-year-old patient who presented to medical attention with palpable axillary adenopathy. Biopsy confirmed poorly differentiated adenocarcinoma. Formal staging revealed extensive metastatic disease to bone and liver. Initial chemotherapy proved ineffective. We describe the diagnostic evaluation, treatment, and achievement of durable remission using a novel sorafenib-based drug combination that was chosen through the application of a functional analytic laboratory platform. CONCLUSION: The clinical management of patients with carcinoma of unknown primary continues to present a considerable challenge for practicing oncologists. Laboratory platforms capable of examining cellular response to injury, growth factor withdrawal, and cytotoxic insult at the level of cellular function may provide insights for drug selection in this patient population. SAGE Publications 2019-03-21 /pmc/articles/PMC6429643/ /pubmed/30915220 http://dx.doi.org/10.1177/2050313X19838739 Text en © The Author(s) 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Report Usón Junior, Pedro Luiz Serrano Wagner, Jairo Corpa, Marcus Vinicius de Nigro Coelho, Iracema Moraes Nagourney, Robert A Yamaguchi, Nise Hitomi Metastatic carcinoma of unknown primary with complete metabolic response following sorafenib-based chemotherapy |
title | Metastatic carcinoma of unknown primary with complete metabolic response following sorafenib-based chemotherapy |
title_full | Metastatic carcinoma of unknown primary with complete metabolic response following sorafenib-based chemotherapy |
title_fullStr | Metastatic carcinoma of unknown primary with complete metabolic response following sorafenib-based chemotherapy |
title_full_unstemmed | Metastatic carcinoma of unknown primary with complete metabolic response following sorafenib-based chemotherapy |
title_short | Metastatic carcinoma of unknown primary with complete metabolic response following sorafenib-based chemotherapy |
title_sort | metastatic carcinoma of unknown primary with complete metabolic response following sorafenib-based chemotherapy |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429643/ https://www.ncbi.nlm.nih.gov/pubmed/30915220 http://dx.doi.org/10.1177/2050313X19838739 |
work_keys_str_mv | AT usonjuniorpedroluizserrano metastaticcarcinomaofunknownprimarywithcompletemetabolicresponsefollowingsorafenibbasedchemotherapy AT wagnerjairo metastaticcarcinomaofunknownprimarywithcompletemetabolicresponsefollowingsorafenibbasedchemotherapy AT corpamarcusviniciusdenigro metastaticcarcinomaofunknownprimarywithcompletemetabolicresponsefollowingsorafenibbasedchemotherapy AT coelhoiracemamoraes metastaticcarcinomaofunknownprimarywithcompletemetabolicresponsefollowingsorafenibbasedchemotherapy AT nagourneyroberta metastaticcarcinomaofunknownprimarywithcompletemetabolicresponsefollowingsorafenibbasedchemotherapy AT yamaguchinisehitomi metastaticcarcinomaofunknownprimarywithcompletemetabolicresponsefollowingsorafenibbasedchemotherapy |